<DOC>
	<DOCNO>NCT02035891</DOCNO>
	<brief_summary>The study aim assess： 1. whether low-dose colchicine could reduce microalbuminuria patient type 2 diabetes microalbuminuria receive stable treatment angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker ( ACEI/ARB ) least 3 month ; 2. whether low-dose colchicine decrease carotid intima-media thickness ( IMT ) patient type 2 diabetes microalbuminuria ; 3. whether low-dose colchicine slow progression microvascular complication patient type 2 diabetes microalbuminuria ; 4. whether low-dose colchicine reduces risk cardiovascular event patient type 2 diabetes microalbuminuria .</brief_summary>
	<brief_title>Low-dose Colchicine Patients With Type 2 Diabetes Mellitus Microalbuminuria</brief_title>
	<detailed_description>BACKGROUND—Previous study report colchicine 0.5 mg/day , addition statin standard secondary prevention therapy , effective prevention cardiovascular event patient stable coronary disease . An experiment conduct Li et al . show twenty-four-hour urinary albumin excretion reduce 6 month colchicine treatment rat diabetic nephropathy.As micro macrovascular complication diabetes closely associate inflammation , anti-inflammation property , colchicine might reduce risk micro macrovascular complication diabetes . STUDY DESIGN—Patients type 2 diabetes microalbuminuria ( 30mg/g Cr≤UACR≤300mg/g Cr ) receive stable dosage ACEI/ARB least 3 month randomize receive colchicine 0.5 mg/day placebo . This trial include four phase : - Phases 1 : A prospective , randomized，double-blind，placebo control study , aim evaluate change Urinary Albumin To Creatinine Ratio ( UACR ) baseline 6th month . - Phases 2 : A prospective , randomized，double-blind，placebo control study , aim evaluate change CIMT baseline 18th month . - Phases 3 : A prospective , randomized，double-blind，control study , aim evaluate microvascular event date randomization third year . - Phases 4 : A prospective , randomized，double-blind，control study , aim evaluate macrovascular microvascular event date randomization 6th year . SAFETY AND DATA MANAGEMENT-Independent Safety Data Monitoring Committee set monitor safety tolerability subject ; committee analyze data independent investigator end one phase .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<criteria>Well informed procedure trial inform consent obtain Voluntarily accept standardize treatment 3070 year old , gender limit Diagnosed type 2 diabetes receive standardized hypoglycemic therapy Have receive stable dos ACEI ARBs least 3 month Two three examination UACR random urine 30300 mg/g Cr ( infection factor rule ) 3 month Well compliance Capable self blood Glucose monitoring Pregnant lactate Type 1 diabetes Poor blood glucose control（HbA1c &gt; 11 % ） A history malignant tumor Abnormal liver renal function ( defined alanine aminotransferase ( ALT ) &gt; 2.5 time higher normal range , eGFR &lt; 30 mL/min per 1•73 m² ) Poor blood pressure control [ systolic blood pressure ( SBP ) &gt; 180mmHg , diastolic blood pressure ( DBP ) &gt; 110mmHg ] With severe heart disease , cardiac function bad grade II , anemia ( Hb &lt; 9.0g/d1 ) Continuous use colchicine nonsteroidal antiinflammatory drug ( except aspirin ) one week recent 3 month History gout Blood routine test indicate white blood cell count ( WBC ) &lt; 3*109/l Body Mass Index ( BMI ) &lt; 18.5 ≥35kg/m2 Drug alcohol abuse Accompanying mental disorder ca n't collaborate Abnormal digestion absorption function Other endocrine diseases Other chronic disease need longterm glucocorticoid treatment With severe infection , immune dysfunction A history colchicine allergies allergic constitution</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>colchicine</keyword>
	<keyword>urinary albumin-to-creatinine ratio</keyword>
	<keyword>carotid Intima-Media Thickness</keyword>
	<keyword>overt nephropathy</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>